All In Biotech

NDA 021527 · Boehringer Ingelheim

Atrovent Hfa

Ipratropium Bromide · Inhalation

Last checked: Nov 20, 2026Latest source record: Dec 30, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2004

Nov 17, 2004

Approved uses

1

Original approval plus efficacy supplements

Registered trials

125

33 Phase 3, 4 recruiting

FAERS reports

36,013

27,436 serious, 4,745 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 5, 2025.

ATROVENT HFA Inhalation Aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. ATROVENT HFA is an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema ( 1 )

Mechanism: Ipratropium bromide is an anticholinergic (parasympatholytic) agent which, based on animal studies, appears to inhibit vagally-mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released at the neuromuscular junctions in the lung. Anticholinergics prevent the increases in intracellular concentration of Ca++ which is caused by interaction of acetylcholine with the muscarinic receptors on bronchial smooth muscle.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ATROVENT HFA · IPRATROPIUM BROMIDE 0.021MG/INH · AEROSOL, METERED, INHALATION · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Ipratropium" as an intervention, any sponsor and status, largest first.

All 125 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea6,130
  • asthma4,095
  • pneumonia3,215
  • cough3,117
  • drug ineffective2,757
  • wheezing2,691
  • fatigue2,285
  • nausea2,040
  • chronic obstructive pulmonary disease1,882
  • off label use1,781
  • diarrhoea1,733
  • malaise1,724

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004946
20051,232
2006912
2007805
2008979
20091,006
20101,009
20111,198
20121,181
20131,068
20141,184
20151,440
20161,832
20171,624
20182,101
20192,339
20202,745
20212,663
20222,005
20231,813
20242,137
20252,103
20261,687

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Atrovent HFA (Ipratropium Bromide)

2024 spending

$115M

Beneficiaries

62,582

200,254 claims

Per beneficiary

$1,842

$36.19 per unit

View as table
YearSpending
2020$131,773,398
2021$133,670,253
2022$134,769,804
2023$131,864,275
2024$115,305,947

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 890 on PubMed

Sponsor: Boehringer Ingelheim

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.